CL2009001050A1 -
Process of preparing a pharmaceutical composition comprising obtaining the hemic acid salt of the acid [r- (r *, r *)] - 2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3 -phenyl-4 - [(phenylamino) carbonyl] -1h-pyrrole-1-heptanoic acid and add a pharmaceutically acceptable carrier to said compound (divisional of application 1301-03).
- Google Patents
Process of preparing a pharmaceutical composition comprising obtaining the hemic acid salt of the acid [r- (r *, r *)] - 2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3 -phenyl-4 - [(phenylamino) carbonyl] -1h-pyrrole-1-heptanoic acid and add a pharmaceutically acceptable carrier to said compound (divisional of application 1301-03).
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert CofiledCriticalWarner Lambert Co
Priority to CL2009001050ApriorityCriticalpatent/CL2009001050A1/en
Publication of CL2009001050A1publicationCriticalpatent/CL2009001050A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Proceso de preparación de una composición farmacéutica que comprende obtener la sal hemicalcica del ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrol-1-heptanoico y adicionar un portador farmacéuticamente aceptable a dicho compuesto (divisional de la solicitud 1301-03).Process of preparing a pharmaceutical composition comprising obtaining the hemicalcic salt of the acid [r- (r *, r *)] - 2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3 -phenyl-4 - [(phenylamino) carbonyl] -1h-pyrrole-1-heptanoic acid and add a pharmaceutically acceptable carrier to said compound (divisional of application 1301-03).
CL2009001050A2009-04-302009-04-30
Process of preparing a pharmaceutical composition comprising obtaining the hemic acid salt of the acid [r- (r *, r *)] - 2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3 -phenyl-4 - [(phenylamino) carbonyl] -1h-pyrrole-1-heptanoic acid and add a pharmaceutically acceptable carrier to said compound (divisional of application 1301-03).
CL2009001050A1
(en)
Process of preparing a pharmaceutical composition comprising obtaining the hemic acid salt of the acid [r- (r *, r *)] - 2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3 -phenyl-4 - [(phenylamino) carbonyl] -1h-pyrrole-1-heptanoic acid and add a pharmaceutically acceptable carrier to said compound (divisional of application 1301-03).
Process of preparing a pharmaceutical composition comprising obtaining the hemic acid salt of the acid [r- (r *, r *)] - 2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3 -phenyl-4 - [(phenylamino) carbonyl] -1h-pyrrole-1-heptanoic acid and add a pharmaceutically acceptable carrier to said compound (divisional of application 1301-03).
Process of preparing a pharmaceutical composition comprising obtaining the hemic acid salt of the acid [r- (r *, r *)] - 2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3 -phenyl-4 - [(phenylamino) carbonyl] -1h-pyrrole-1-heptanoic acid and add a pharmaceutically acceptable carrier to said compound (divisional of application 1301-03).
Process of preparing a pharmaceutical composition comprising obtaining the hemic acid salt of the acid [r- (r *, r *)] - 2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3 -phenyl-4 - [(phenylamino) carbonyl] -1h-pyrrole-1-heptanoic acid and add a pharmaceutically acceptable carrier to said compound (divisional of application 1301-03).
Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
IMPROVED PROCESS FOR THE PREPARATION OF [3R,5R]-2-FLUOROPHENYL-β,δ- DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(2-HYDROXYPHENYLAMINO)- CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID, SODIUM SALT
HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-β, δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
Novel crystalline form of semi-calcium [r-(r ,r)]-2-(4-fluorophenyl)-beta, dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl)-1h-pyrrole-1-heptanic salt (athorovastatin), method of obtaining same, pharmacological composition containing such salt and medical application thereof
Hydrolysis of [R(R*,R*)]-2-(4-Fluorophenyl)-b,D-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic acid esters with calcium hydroxide.